Keyphrases
Chemosensitive
100%
Relapsed or Refractory
100%
Non-small Cell Lung Cancer (NSCLC)
100%
Phase II Trial
100%
Gefitinib
100%
Oncology
100%
Chemorefractory
100%
Small Cell Lung Cancer
57%
Prior Chemotherapy
42%
Epidermal Growth Factor Receptor
28%
Stable Disease
28%
Chemotherapy Regimen
28%
Eastern Cooperative Oncology Group Performance Status (ECOG PS)
28%
Hyperglycemia
14%
Disease Progression
14%
Overexpression
14%
Chemoresistant
14%
Clinical Trials
14%
Tumor Growth
14%
Diarrhea
14%
Overall Survival
14%
Pathologic
14%
Patient Characteristics
14%
Median Time
14%
Complete Response
14%
Partial Response
14%
Dyspnea
14%
Progressive Disease
14%
Rash
14%
Control Rate
14%
Best Response
14%
Prior Treatment
14%
Neuroendocrine Tumor
14%
Sensitive Diseases
14%
Time to Progression
14%
Pulmonary Toxicity
14%
Two-stage Design
14%
Metastatic Merkel Cell Carcinoma
14%
Clinical Control
14%
End-organ Function
14%
Chemorefractory Disease
14%
Medicine and Dentistry
Oncology
100%
Phase II Trials
100%
Gefitinib
100%
Small-Cell Carcinoma
100%
Disease
57%
Small Cell Lung Cancer
57%
Non Small Cell Lung Cancer
42%
Patient History of Chemotherapy
42%
Epidermal Growth Factor Receptor
28%
Chemotherapy Regimens
28%
Clinical Trial
14%
Diarrhea
14%
Overall Survival
14%
Disease Exacerbation
14%
Hyperglycemia
14%
Patient Characteristics
14%
Tumor Progression
14%
Progressive Disease
14%
Exanthem
14%
Dyspnea
14%
Side Effect
14%
Neuroendocrine Tumor
14%
Pulmonary Toxicity
14%
Merkel Cell Carcinoma
14%
Pharmacology, Toxicology and Pharmaceutical Science
Phase II Trials
100%
Gefitinib
100%
Small Cell Carcinoma
100%
Disease
71%
Small Cell Lung Cancer
57%
Non Small Cell Lung Cancer
42%
Patient History of Chemotherapy
42%
Epidermal Growth Factor Receptor
28%
Chemotherapy Regimens
28%
Hyperglycemia
14%
Clinical Trial
14%
Tumor Growth
14%
Diarrhea
14%
Overall Survival
14%
Side Effect
14%
Disease Exacerbation
14%
Dyspnea
14%
Rash
14%
Lung Toxicity
14%
Neuroendocrine Tumor
14%
Merkel Cell Carcinoma
14%